THE DEAL, AT A GLANCE
From the announcementFog Pharmaceuticals
01What it doesThe new capital is framed around Advance FOG-001 MDM2/MDMX dual inhibitor through IND filing.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedFog Pharmaceuticals raised $61M Series BFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersFog Pharmaceuticals is positioned around AI-designed macrocyclic peptides for intracellular cancer targets that antibodies cannot reach.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Fog Pharmaceuticals · Financing Record
Explore source-linked visual explanations for Fog Pharmaceuticals. Unsupported claims are withheld while source review continues.
Record 1121 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →